Cargando…
Prognostic value of claudin 18.2 expression in gastric adenocarcinoma
BACKGROUND: Claudin 18.2 (CLDN18.2) is a cell surface protein expressed by gastric cancer cells. The monoclonal antibody zolbetuximab binds CLDN18.2-positive cancer cells and causes cancer cell death. A few studies researched the prognostic effect of CLDN18.2 expression in metastatic gastric adenoca...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9994048/ https://www.ncbi.nlm.nih.gov/pubmed/36908327 http://dx.doi.org/10.4251/wjgo.v15.i2.343 |
_version_ | 1784902600541339648 |
---|---|
author | Kayikcioglu, Erkan Yüceer, Ramazan Oğuz Cetin, Bulent Yüceer, Kamuran Karahan, Nermin |
author_facet | Kayikcioglu, Erkan Yüceer, Ramazan Oğuz Cetin, Bulent Yüceer, Kamuran Karahan, Nermin |
author_sort | Kayikcioglu, Erkan |
collection | PubMed |
description | BACKGROUND: Claudin 18.2 (CLDN18.2) is a cell surface protein expressed by gastric cancer cells. The monoclonal antibody zolbetuximab binds CLDN18.2-positive cancer cells and causes cancer cell death. A few studies researched the prognostic effect of CLDN18.2 expression in metastatic gastric adenocarcinoma. AIM: To identify the prognostic value of CLDN18.2 expression in patients with metastatic gastric adenocarcinoma. METHODS: This study was conducted with 65 patients over the age of 18 who were diagnosed with metastatic gastric adenocarcinoma. We investigated the effect of CLDN18.2 expression on clinicopathological characteristics (age, sex, histological grade, Lauren classification, family history, metastatic site, HER2 expression) and prognosis for patients with metastatic gastric adenocarcinoma. RESULTS: CLDN18.2 expression was positive in 73.8% (48) of the patients. During the median 17.7-mo follow-up period, 89.2% (58) of the patients died. Median progression-free survival and overall survival (OS) were 6 mo (95% confidence interval: 1.6-10.4) and 12 mo (95% confidence interval: 7.5-16.5). There was no statistically significant correlation between CLDN18.2 expression and clinicopathological characteristics of the patients. In univariate and multivariate Cox regression analysis, there was no correlation between clinicopathological characteristics of patients and progression-free survival or OS. CONCLUSION: CLDN18.2 expression was quite high in patients with gastric adenocarcinoma, identifying the proportion of the patients in whom zolbetuximab would be efficacious. There is no statistically significant correlation with clinicopathological characteristics and OS. CLDN18.2 is not a prognostic marker in patients with gastric adenocarcinoma, although it is predictive. |
format | Online Article Text |
id | pubmed-9994048 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-99940482023-03-09 Prognostic value of claudin 18.2 expression in gastric adenocarcinoma Kayikcioglu, Erkan Yüceer, Ramazan Oğuz Cetin, Bulent Yüceer, Kamuran Karahan, Nermin World J Gastrointest Oncol Retrospective Cohort Study BACKGROUND: Claudin 18.2 (CLDN18.2) is a cell surface protein expressed by gastric cancer cells. The monoclonal antibody zolbetuximab binds CLDN18.2-positive cancer cells and causes cancer cell death. A few studies researched the prognostic effect of CLDN18.2 expression in metastatic gastric adenocarcinoma. AIM: To identify the prognostic value of CLDN18.2 expression in patients with metastatic gastric adenocarcinoma. METHODS: This study was conducted with 65 patients over the age of 18 who were diagnosed with metastatic gastric adenocarcinoma. We investigated the effect of CLDN18.2 expression on clinicopathological characteristics (age, sex, histological grade, Lauren classification, family history, metastatic site, HER2 expression) and prognosis for patients with metastatic gastric adenocarcinoma. RESULTS: CLDN18.2 expression was positive in 73.8% (48) of the patients. During the median 17.7-mo follow-up period, 89.2% (58) of the patients died. Median progression-free survival and overall survival (OS) were 6 mo (95% confidence interval: 1.6-10.4) and 12 mo (95% confidence interval: 7.5-16.5). There was no statistically significant correlation between CLDN18.2 expression and clinicopathological characteristics of the patients. In univariate and multivariate Cox regression analysis, there was no correlation between clinicopathological characteristics of patients and progression-free survival or OS. CONCLUSION: CLDN18.2 expression was quite high in patients with gastric adenocarcinoma, identifying the proportion of the patients in whom zolbetuximab would be efficacious. There is no statistically significant correlation with clinicopathological characteristics and OS. CLDN18.2 is not a prognostic marker in patients with gastric adenocarcinoma, although it is predictive. Baishideng Publishing Group Inc 2023-02-15 2023-02-15 /pmc/articles/PMC9994048/ /pubmed/36908327 http://dx.doi.org/10.4251/wjgo.v15.i2.343 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Retrospective Cohort Study Kayikcioglu, Erkan Yüceer, Ramazan Oğuz Cetin, Bulent Yüceer, Kamuran Karahan, Nermin Prognostic value of claudin 18.2 expression in gastric adenocarcinoma |
title | Prognostic value of claudin 18.2 expression in gastric adenocarcinoma |
title_full | Prognostic value of claudin 18.2 expression in gastric adenocarcinoma |
title_fullStr | Prognostic value of claudin 18.2 expression in gastric adenocarcinoma |
title_full_unstemmed | Prognostic value of claudin 18.2 expression in gastric adenocarcinoma |
title_short | Prognostic value of claudin 18.2 expression in gastric adenocarcinoma |
title_sort | prognostic value of claudin 18.2 expression in gastric adenocarcinoma |
topic | Retrospective Cohort Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9994048/ https://www.ncbi.nlm.nih.gov/pubmed/36908327 http://dx.doi.org/10.4251/wjgo.v15.i2.343 |
work_keys_str_mv | AT kayikciogluerkan prognosticvalueofclaudin182expressioningastricadenocarcinoma AT yuceerramazanoguz prognosticvalueofclaudin182expressioningastricadenocarcinoma AT cetinbulent prognosticvalueofclaudin182expressioningastricadenocarcinoma AT yuceerkamuran prognosticvalueofclaudin182expressioningastricadenocarcinoma AT karahannermin prognosticvalueofclaudin182expressioningastricadenocarcinoma |